참고문헌
- Aaron JS, Suet YL, Jane J, et al (2008). Micro RNA Expression Profiles Associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425-36. https://doi.org/10.1001/jama.299.4.425
- Bulavin DV, Demidov ON, Saito S, et al (2002). Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet, 31, 210-5. https://doi.org/10.1038/ng894
- Castellino RC, De Bortoli M, Lu X, et al (2008). Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol, 86, 245-56. https://doi.org/10.1007/s11060-007-9470-8
- Ding PR, Wan DS, Pan ZZ, et al (2006). Prognostic analysis of 384 male patients with rectal cancer. Cancer, 25, 1158-61.
- Doucette TA, Yang Y, Pedone C, et al (2012). WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma. Neurosurgery, 70, 1002-10.
- Fiscella M, Zhang H, Fan S, et al (1997). Wip1, a novel human prote in phosphatase that is induced in response to ionizing radiation in a p53 - dependent manner. Proc Natl A cad Sci USA, 94, 6048-53. https://doi.org/10.1073/pnas.94.12.6048
- Fuku T, Semba S, Yutori H, Yokozaki H (2007). Increased wildtype p53 induced phosphatase1 (Wipl or PPM1D) expression correlated with downregulation of checkpoint kinase2 in human gastric carcinoma. Pathol Int, 57, 566-71. https://doi.org/10.1111/j.1440-1827.2007.02140.x
- Hayashi R, Tanoue K, Durell SR, et al (2011). Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1). Biochemistry, 50, 4537-49. https://doi.org/10.1021/bi101949t
- Hirasawa A, Saito-Ohara F, Inoue J, et a1 (2003). Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res, 10, 1995-2004.
- Hu W, Feng Z, Modica I, et al (2010). Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer, 1, 360-8. https://doi.org/10.1177/1947601910371979
- Le Cuezennec X, Bulavin DV (2010). WIP1 phosphatase at the crossroads of cancer and aging. Trends Biochem Sci, 35, 109-14,. https://doi.org/10.1016/j.tibs.2009.09.005
- Liang C, Guo E, Lu S, et al (2012). Over-expression of wildtype p53-induced phosphatase 1 confers poor prognosis of patients with gliomas. Brain Res, 1444, 65-75,. https://doi.org/10.1016/j.brainres.2011.12.052
- Loukopoulos P, Shibata T, Katoh H, et a1 (2007). Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma, identification of genetic indicators that predict patient outcome. Cancer Sci, 98, 392-400. https://doi.org/10.1111/j.1349-7006.2007.00395.x
- Lu X, Bocangel D, Nannenga B, et al (2004). The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell, 15, 621-34. https://doi.org/10.1016/j.molcel.2004.08.007
- Lu X, Nannenga B and Donehower LA (2005). PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev, 19, 1162-74. https://doi.org/10.1101/gad.1291305
- Park JY, Song JY, Kim HM, et al (2012). P53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors. Int J Biochem Cell Biol, 44, 896-904. https://doi.org/10.1016/j.biocel.2012.02.013
- Ren WM, Zhang YY, Luo JF (2012). The PPM1D expression and significance in papillary thyroid carcinoma. Pro Bed Experim Pathol, 28, 623-6.
- Saito OF, Imoto I, Inoue J, et al (2003). PPM1D is a potential target for 17q gain in neurob lastoma. Cancer Res, 63, 1876-83.
- Satoh N, Maniwa Y, Bermudez VP, et al (2011). Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci, 102, 1101-6. https://doi.org/10.1111/j.1349-7006.2011.01898.x
- Shreeram S, Demidov ON, Hee WK, et al (2006). Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell, 23, 754-64.
- Spinnler C, Hedstrom E, Li H, et al (2011). Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death Differ, 18, 1736-45. https://doi.org/10.1038/cdd.2011.45
- Wan D (2009). Epidemiologic trend of and strategies for colorectal cancer. Chin J Cancer, 9, 897-902.
- Wang P, Rao J, Yang H, Zhao H, Yang L (2011). Wip1 overexpression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas. J Surg Oncol, 104, 679-84. https://doi.org/10.1002/jso.22004
- Yu E, Ahn YS, Jang SJ, et al (2007). Over expression of the wip1 gene abrogates the p38 MAPK/P53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat, 101, 269-78. https://doi.org/10.1007/s10549-006-9304-y
피인용 문헌
- DEPTOR Expression Negatively Correlates with mTORC1 Activity and Tumor Progression in Colorectal Cancer vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4589
- Down-regulated MYH11 Expression Correlates with Poor Prognosis in Stage II and III Colorectal Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7223
- WIP1 regulates the proliferation and invasion of nasopharyngeal carcinoma in vitro vol.35, pp.8, 2014, https://doi.org/10.1007/s13277-014-2034-6
- Hedgehog Signaling in the Maintenance of Cancer Stem Cells vol.7, pp.3, 2015, https://doi.org/10.3390/cancers7030851
- Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC vol.15, pp.2, 2016, https://doi.org/10.3892/mmr.2016.6032
- Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6361